Rialto, CANCT07358546Now EnrollingIRB Ready

Non-alcoholic Fatty Liver Disease Clinical Trial in Rialto, CA

Access cutting-edge non-alcoholic fatty liver disease treatment through this clinical trial at a research site in Rialto. Study-provided care at no cost to qualified participants.

Sponsored by GlaxoSmithKline

Quick Self-Assessment

See if you qualify for this Rialto location

Preparing your pre-screening questions…

Expert Care in Rialto

Access non-alcoholic fatty liver disease specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related non-alcoholic fatty liver disease treatment provided free

Apply for This Rialto Location

Check if you qualify for this non-alcoholic fatty liver disease clinical trial in Rialto, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Rialto

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Rialto site if eligible
  4. 4Begin participation

About This Non-alcoholic Fatty Liver Disease Study in Rialto

This study is designed to study the pharmacokinetic (PK) and safety profiles of a single dose of efimosfermin alfa in participants with varying degrees of Hepatic Impairment (HI) (assessed by Child-Pugh score) due to steatotic liver disease, with and without significant alcohol consumption.

Sponsor: GlaxoSmithKline

Who Can Participate

Inclusion Criteria

Between 18 years and 70 years of age inclusive
Body Mass Index (BMI) within the range 23-40 kilogram per square meter (kg/m\^2)
Male or female participants
Participant has liver cirrhosis with a grade of hepatic impairment that can be classified as a discrete Child-Pugh class. Participants must:
Have a clinical diagnosis of liver cirrhosis in the participant's medical history corroborated by previous liver biopsy, medical imaging or compatible biochemical profile, and
Be classed during Screening as one of the following Child-Pugh classes:
Child-Pugh B: Score 7-9 or
Child-Pugh C: Score 10-15
Chronic (greater than \[\>\] 6 months) HI which is currently stable (no acute episodes of illness within the previous 1 month prior to Screening (Visit 1) due to deterioration in hepatic function). Participants must also remain stable throughout the Screening period. Assessment of the stability of the participant's hepatic function will be determined by the investigator.

Exclusion Criteria

History of extrahepatic disorders possibly related to etiology of cirrhosis.
History of cryoglobulinemia.
Participants with Grade 3 ascites or refractory ascites.
Participants with refractory encephalopathy or significant central nervous system disease
History of gastric or esophageal variceal bleeding within the past 6 months and for which varices have not been adequately treated with medication and/or surgical procedures.
Other primary causes of liver disease. Steatotic liver disease must be the primary cause of liver disease.
Clinically significant abnormalities affecting physical health in medical history, or on physical examination, that could interfere with or for which treatment could interfere with the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the participant in this study.
Current, or history of known hepatocellular carcinoma (HCC).
Participants with transjugular intrahepatic portosystemic shunt (TIPS) placement.
Presence of hepatopulmonary or hepatorenal syndrome.
Presence of primarily cholestatic liver diseases.
Evidence of symptomatic or complicated cholecystitis.
History of pancreatic injury, pancreatitis, or other pancreatic disease.
History of liver transplantation, or active on the liver transplant waiting list.
Participants with signs of active infection
History of adrenal gland disease or using treatment that affects the hypothalamic-pituitary-adrenal axis.
History of significant bone disease such as osteoporosis
Psychosocial features that, in the opinion of the investigator, increase the likelihood of loss to follow-up.
History or presence of drug abuse.
Use of other investigational drugs at the time of screening, or within 5 half-lives or 30 days prior to study intervention, whichever was longer; or longer if required by local regulations
Have previously taken efimosfermin alfa
Participants with Alanine Aminotransferase (ALT) value \>3 times (x) upper limit of normal (ULN)
Participants with Aspartate aminotransferase (AST) value \>=300 Units/Liter.
Participants with estimated glomerular filtration rate (eGFR) (Chronic Kidney Disease Epidemiology \[CKD-Epi\] 2021) \<45 milliliter/minute/1.73 square meter (mL/min/1.73m\^2).
Average of triplicate QT interval corrected for heart rate using Fridericia formula (QTcF) \>480 milliseconds (msec) (for male and female participants) at Screening
For participants in the MASH with alcohol category, significant risk of withdrawal symptoms.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Rialto?

Yes, this clinical trial (NCT07358546) has an active research site in Rialto, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Non-alcoholic Fatty Liver Disease Treatment Options in Rialto, CA

If you're searching for non-alcoholic fatty liver disease treatment options in Rialto, CA, this clinical trial (NCT07358546) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Rialto research site is actively enrolling participants for this clinical trial. You'll receive care from experienced non-alcoholic fatty liver disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all non-alcoholic fatty liver disease clinical trials near you to find additional studies recruiting in your area.

More Ankylosing Spondylitis Trials in Rialto, CA

See all ankylosing spondylitis clinical trials recruiting in Rialto — not just this study.

Browse Ankylosing Spondylitis Trials in Rialto →

Browse More Trials by Condition

Ankylosing Spondylitis TrialsNASH TrialsLiver Disease TrialsInterstitial Cystitis TrialsNon-Alcoholic Fatty Liver Disease TrialsFanconi Anemia TrialsAll Conditions →

Ready to Join in Rialto?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Rialto, CA